A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.

ABSTRACT:

Background

Cytoreductive nephrectomy (CN) for the treatment of metastatic renal cell carcinoma (mRCC) was called into question following the publication of the CARMENA trial. While previous retrospective studies have supported CN alongside targeted therapies, there is minimal research establishing its role in conjunction with immune checkpoint inhibitor (ICI) therapy.

Objective

To evaluate the association between CN and oncological outcomes in patients with mRCC treated with immunotherapy.

Materials and methods

A multicenter retrospective cohort study of patients diagnosed with mRCC between 2000 and 2020 who were treated at the Seattle Cancer Care Alliance and The Ohio State University and who were treated with ICI systemic therapy (ST) at any point in their disease c

SUBMITTER: Gross EE 

PROVIDER: S-EPMC10938342 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature